alexa Commentary: Effect of Agalsidase Beta on Corneal Verticillata in Patients with Fabry Disease | Open Access Journals
ISSN: 2155-9570
Journal of Clinical & Experimental Ophthalmology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Commentary: Effect of Agalsidase Beta on Corneal Verticillata in Patients with Fabry Disease

Joshua Mali and Albert M. Morier*
Department of Ophthalmology, Albany Medical College, USA
*Corresponding Author : Albert M. Morier
Associate Clinical Professor of Ophthalmology Albany Medical College
Ophthalmology, 100 Willow St Guilderland
NY 12084, United States
Tel: 1518456-7687
Fax: 1518 355-1208
E-mail: [email protected]om
Received: February 27, 2016Accepted: January 30, 2016 Published:February 02, 2016
Citation:Mali J, Morier AM (2016) Commentary: Effect of Agalsidase Beta on Corneal Verticillata in Patients with Fabry Disease. J Clin Exp Ophthalmol 7:528. doi:10.4172/2155-9570.1000528
Copyright: © 2015 Mali J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Visit for more related articles at Journal of Clinical & Experimental Ophthalmology

Commentary
In our previous article entitled, "Ocular manifestations of Fabry disease within in single kindred", we describe the ocular and systemic manifestations of Fabry disease. Fabry disease is a lysosomal storage disease inherited in an X-linked fashion which results in deficient enzyme levels of alpha-galactosidase A (AGAL), an enzyme important for the breakdown of various glycoproteins in the body. AGAL deficiency prevents the effective metabolism of the glycoprotein globotriaosylceramide (Gb3). Consequently, Gb3 deposits within lysosomes in virtually every tissue in the body including the eyes, kidneys, brain, and heart. Increasing storage of Gb3 and the resultant intrinsic inflammatory reactions lead to increased disease burden in the patient with disease progression. The initial symptoms can include angiokeratomas (telangiectatic cutaneous lesions), acroparesthesia (severe pain in hands and feet), hypohidrosis (inability to sweat), gastrointestinal dysmotility, and various ocular manifestations [1].
The most commonly reported ocular finding is corneal verticillata, a bilateral, whorl-like pattern of cream-colored lines usually found in the inferior cornea. These lines are caused by the accumulation of Gb3 at the level of Bowman’s membrane, which radiate out in a vortex pattern. In a slit lamp examination, the degree of corneal verticillata can range from very faint to quite obvious but rarely affects visual acuity though glare has been reported.
Agalsidase beta is recombinant alpha-galactosidase A enzyme and has revolutionized the treatment of Fabry patients. While this enzyme has shown to alleviate symptoms and progression of Fabry disease, there has been no study to date evaluating the effect on corneal verticillata and whether or not resolution occurs [2].
We presented our data at the 2015 American Academy of Ophthalmology (AAO) Annual Meeting in which thirteen Fabry patients with documented corneal verticillata on examination and being treated at that time with enzyme replacement therapy (agalsidase beta) participated in our analysis. On two year follow-up, careful slit lamp examinations were performed to analyze the anterior segment for the presence or resolution of corneal verticillata. Three out of the thirteen patients (23%) had complete resolution of corneal verticillata in both eyes.
All evaluated Fabry patients were being treated with agalsidase beta and had corneal verticillata, which generally does not affect vision and is readily recognizable by slit lamp examination. Corneal verticillata in patients with Fabry disease appear to resolve in about a quarter of patients when treated with agalsidase beta.
These results provide objective clinical evidence of the efficacy of enzyme replacement therapy (ERT) in Fabry disease. Whether the resolution of corneal verticillata with ERT can be a clinical gauge to the patient’s response to therapy is still under investigation and is a promising premise for future studies.
Overall, the eye care provider can play a crucial role in the early recognition of ocular manifestations of Fabry disease and decrease both the time to accurate diagnosis and the delay in the institution of disease-modifying therapy.
References
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 7847
  • [From(publication date):
    March-2016 - Sep 26, 2017]
  • Breakdown by view type
  • HTML page views : 7799
  • PDF downloads :48

Review summary

  1. Tim Kohler
    Posted on Jul 15 2016 at 5:00 pm
    The article explains the ocular and systemic manifestations of Fabry diseases. The commentary briefly narrates the pathophysiology and the currently used treatment measures for the disease. The article also highlights the problems associated with Corneal Verticillata and the efficacy of Agalsidase Beta in the treatment of fabry disease associated Corneal Verticillata.
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords